Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

MRI-Guided SBRT Could Represent Safer, More Precise Radiotherapy Option for Prostate Cancer

February 2nd 2023

Amar U. Kishan, MD, discusses the safety results of MRI-guided SBRT compared with the current standard of care, highlights the benefits of using an MRI to guide radiation for patients with prostate cancer, and explains other areas where MRI-guided SBRT could explored.

Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC

February 1st 2023

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.

Researcher Highlights Need for Improved Understanding of Prostate Basal Cell Carcinoma

January 31st 2023

Basal cell carcinoma of the prostate is a rare variant of prostate cancer so uncommon that few physicians will ever treat the disease in their careers. Only 100 or so patients have been identified in the literature compared with more than 1 million diagnoses every year for adenocarcinoma.

Dr. Kishan on the MIRAGE Trial of MRI-Guided SBRT in Prostate Cancer

January 30th 2023

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

KEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility

January 25th 2023

Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic hormone-sensitive prostate cancer due to futility.

Novel Combinations Promote Individualized Care in Bladder and Prostate Cancer

January 24th 2023

Alicia Morgans, MD, MPH, discussed the evolving role of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, investigational immunotherapy combinations in urothelial cancer, and how antibody-drug conjugates provide a unique means of delivering toxic agents directly to tumors.

Dr. Fecteau on Salvage Therapy for Recurrent Prostate Cancer

January 20th 2023

Ryan Fecteau, MD, PhD, discusses the navigation of salvage treatment options for patients experiencing isolated prostate cancer recurrence.

Dr. Morgans on the Current Treatment Landscape For mHSPC

January 18th 2023

Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.

MRI-Guided Radiotherapy Significantly Reduces Genitourinary, Gastrointestinal AEs in Prostate Cancer

January 17th 2023

Patients who received MRI-guided stereotactic body radiotherapy for prostate cancer experienced fewer moderate acute physician-scored genitourinary and gastrointestinal adverse effects compared with those who received computed tomography–guided stereotactic body radiotherapy.

Dr. Dorff on the Exploration of Triplet Combination Therapies in mHSPC

January 12th 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

ADXS-504 Study Increases Enrollment After Confirming Safety in Recurrent Early Prostate Cancer

January 12th 2023

ADXS-504, an investigational off-the-shelf neoantigen therapy, has been reported to be well tolerated and safe in patients with biochemically recurrent early prostate cancer.

BXCL701 Plus Pembrolizumab Generates Promising Responses in Small Cell Neuroendocrine mCRPC

January 11th 2023

The combination of BXCL701 and pembrolizumab produced encouraging responses in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to topline data from a phase 2 trial.

Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC

January 10th 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Metastatic CRPC Management: Future Directions in Care

January 9th 2023

Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.

TAVT-45 Granules Show Equivalence to Abiraterone Tablets in Metastatic Prostate Cancer

January 5th 2023

Abiraterone acetate granules for oral suspension demonstrated therapeutic equivalence and comparable safety to the original formulation of abiraterone acetate in patients with metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Addressing Barriers to Care in Metastatic Castration-Resistant Prostate Cancer

January 2nd 2023

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.

Metastatic CRPC: Selecting Patients for Cabazitaxel or Radiotherapy

January 2nd 2023

Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.

A “Crazy” Idea Leads to a Revolution in Prostate Cancer Care

December 28th 2022

An unshakeable belief in the power of the immune system and a deep-seated desire to make the world a better place have guided Eric J. Small, MD, throughout his career.

Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC

December 26th 2022

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.

Metastatic CRPC: Considering Use of Combination Cabazitaxel/Carboplatin

December 26th 2022

Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.